YIDU TECH (02158) repurchased over 9.5 million Hong Kong dollars five times this week, jointly launched the first domestic "AI + health management" innovative system with Nanshan Hospital.
On January 30, iCarbonX Technology (02158) continued to increase its buyback actions.
On January 30th, YIDU TECH (02158) continued to increase its share buyback actions. The company announced on that day that it had repurchased 786,000 shares at approximately HK$5.8 per share, costing over HK$4.5 million. The total amount of buybacks in the past 5 days exceeded HK$9.5 million, showing the company's confidence in its long-term value.
In terms of business cooperation, the company has made new progress. Shenzhen Nanshan District People's Hospital and YIDU TECH have officially reached a strategic partnership, jointly releasing the first domestic "AI + Health Management" innovative system that covers "all time, all areas, all demographics, and all stages" to build an AI medical ecosystem from research and development, application to transformation. The press conference was held in Shenzhen, with representatives from the government, enterprises, and medical institutions in attendance, marking another important step in its implementation of smart healthcare scenarios.
Recently, YIDU TECH has been actively expanding in the capital market and business development. It has announced that the number of insured individuals under the "Beijing Inclusive Health Security" operation it is responsible for has exceeded 4.5 million for the year 2026, and it has collaborated with the First Affiliated Hospital of Chongqing Medical University to launch the "General Medicine Diagnosis and Treatment AI Assistant" and other developments. Market observers believe that the continuous share buybacks and multiple business cooperation agreements highlight the company's strategic layout of "technological breakthroughs + scenario implementation," further deepening its influence in the field of medical intelligence and inclusive health.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


